For the second year running, ROVI has obtained the best ranking in the pharmaceutical industry category in the world rating of ESG risks drawn up by Sustainalytics
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults
ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE)
The objective of the new three-monthly formulation is to reach bioequivalence in the plasma levels of letrozole in comparison with the daily administration of oral doses of Femara® 2.5 mg
Created a Chair to study the psychological impact and benefits of technology in mental health prevention
The objective is to help improve society’s mental health and take advantage of the opportunities the new technologies offer to enhance the quality of life and the care that people receive.
The group is collaborating with ReTree to recover an area of the Sierra del Rincón through reforestation with native tree species
BioSim strengthens its national representation with the incorporation of ROVI Pharmaceutical Laboratories
ROVI joins BioSim to strengthen initiatives that promote greater access to and knowledge about biosimilar medicines.